Yuko Palesch to Cerebral Hemorrhage
This is a "connection" page, showing publications Yuko Palesch has written about Cerebral Hemorrhage.
Connection Strength
2.829
-
Statistical analysis plan for pooled individual patient data from two landmark randomized trials (INTERACT2 and ATACH-II) of intensive blood pressure lowering treatment in acute intracerebral hemorrhage. Int J Stroke. 2019 04; 14(3):321-328.
Score: 0.569
-
Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) II: design, methods, and rationale. Neurocrit Care. 2011 Dec; 15(3):559-76.
Score: 0.352
-
Regional Differences in the Response to Acute Blood Pressure Lowering After Cerebral Hemorrhage. Neurology. 2021 02 02; 96(5):e740-e751.
Score: 0.164
-
Sex Differences in Blood Pressure-Lowering Therapy and Outcomes Following Intracerebral Hemorrhage: Results From ATACH-2. Stroke. 2020 08; 51(8):2282-2286.
Score: 0.160
-
Late Neurological Deterioration after Acute Intracerebral Hemorrhage: A post hoc Analysis of the ATACH-2 Trial. Cerebrovasc Dis. 2020; 49(1):26-31.
Score: 0.155
-
Deferoxamine mesylate in patients with intracerebral haemorrhage (i-DEF): a multicentre, randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2019 05; 18(5):428-438.
Score: 0.146
-
Clinical Outcomes Depending on Acute Blood Pressure After Cerebral Hemorrhage. Ann Neurol. 2019 01; 85(1):105-113.
Score: 0.144
-
Intensive Blood-Pressure Lowering in Cerebral Hemorrhage. N Engl J Med. 2016 12 08; 375(23):e48.
Score: 0.125
-
Intensive Blood-Pressure Lowering in Patients with Acute Cerebral Hemorrhage. N Engl J Med. 2016 09 15; 375(11):1033-43.
Score: 0.120
-
Increased brain volume among good grade patients with intracerebral hemorrhage. Results from the Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) study. Neurocrit Care. 2014 Jun; 20(3):470-5.
Score: 0.105
-
High dose deferoxamine in intracerebral hemorrhage (HI-DEF) trial: rationale, design, and methods. Neurocrit Care. 2013 Oct; 19(2):257-66.
Score: 0.100
-
Reliability of hematoma volume measurement at local sites in a multicenter acute intracerebral hemorrhage clinical trial. Stroke. 2013 Jan; 44(1):237-9.
Score: 0.094
-
Systolic blood pressure reduction and risk of acute renal injury in patients with intracerebral hemorrhage. Am J Med. 2012 Jul; 125(7):718.e1-6.
Score: 0.091
-
[Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH)-II at Japan site: study design and advance construction of domestic research network]. Rinsho Shinkeigaku. 2012; 52(9):642-50.
Score: 0.088
-
Association of serum glucose concentrations during acute hospitalization with hematoma expansion, perihematomal edema, and three month outcome among patients with intracerebral hemorrhage. Neurocrit Care. 2011 Dec; 15(3):428-35.
Score: 0.088
-
Safety and tolerability of deferoxamine mesylate in patients with acute intracerebral hemorrhage. Stroke. 2011 Nov; 42(11):3067-74.
Score: 0.086
-
The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--II: neurologic outcome and efficacy analysis. Stroke. 2006 Aug; 37(8):2107-14.
Score: 0.060
-
J-shape relation of blood pressure reduction and outcome in acute intracerebral hemorrhage: A pooled analysis of INTERACT2 and ATACH-II individual participant data. Int J Stroke. 2022 12; 17(10):1129-1136.
Score: 0.044
-
Intensive blood pressure lowering with nicardipine and outcomes after intracerebral hemorrhage: An individual participant data systematic review. Int J Stroke. 2022 06; 17(5):494-505.
Score: 0.043
-
Blood Pressure-Attained Analysis of ATACH 2 Trial. Stroke. 2018 06; 49(6):1412-1418.
Score: 0.034
-
Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013 Mar 07; 368(10):893-903.
Score: 0.024
-
Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke. 2011 Jan; 42(1):227-76.
Score: 0.020
-
The ALIAS Pilot Trial: a dose-escalation and safety study of albumin therapy for acute ischemic stroke--I: Physiological responses and safety results. Stroke. 2006 Aug; 37(8):2100-6.
Score: 0.015